18 A phase 2, open-label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab

Authors
Category Primary study
JournalImmunobiology
Year 2023
This article has no abstract
Epistemonikos ID: 21388a72e7d52359ff21544208c0a8bfd170cbaf
First added on: Feb 16, 2025